Skip to content

Effectiveness of Behavioral Activation Treatment for Schizophrenia

Effectiveness of Non Face-to-face Behavioral Activation Treatment for Negative Symptoms of Schizophrenia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05764148
Enrollment
80
Registered
2023-03-10
Start date
2021-03-01
Completion date
2023-12-31
Last updated
2023-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behavioral Activation, Negative Symptoms in Schizophrenia, Remote Medical Service, Schizophrenia, Latent

Keywords

Schizophrenia, Negative Symptoms in Schizophrenia, behavioral activation, Remote Medical Service

Brief summary

The purpose of this study is to implement a behavior activation remote program for negative symptoms of schizophrenia and to verify whether the behavior activation remote program for negative symptoms of schizophrenia has effects on negative symptoms, cognitive function, and social function of schizophrenia.

Interventions

BEHAVIORALbehavioral activation

Behavioral Activation (BA) is a specific CBT skill. It can be a treatment all by itself, or can be used alongside other CBT skills such as cognitive restructuring. Behavioral activation helps us understand how behaviors influence emotions, just like cognitive work helps us understand the connection between thoughts and emotions.

Sponsors

Inha University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

schizophrenia group and treatment as usual

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients who have received a primary diagnosis of schizophrenia * Patients who are at least 18 years old and under 65 years old * Patients who show a score of 3 or higher on at least two negative symptom items in the Positive and Negative Syndrome Scale (PANSS) * The subject selection period is until December 31, 2021, from the IRB approval date.

Exclusion criteria

* Patients with a history of organic brain syndrome, epilepsy, or traumatic brain injury * Patients with comorbidities such as intellectual disability, current alcohol or other substance dependence * Patients who show a score of 5 or higher on at least two positive symptom items in the Positive and Negative Syndrome Scale (PANSS) * Patients who have received a diagnosis of major depressive disorder according to the DSM-V criteria by a specialist in psychiatry * Patients who have received psychological services including components of behavioral activation therapy * Patients who are at risk of self-harm or harm to others.

Design outcomes

Primary

MeasureTime frameDescription
negative functionthree monthimproved negative function

Secondary

MeasureTime frameDescription
cognitive functionthree monthimproved cognitive function
depressed moodthree monthimproved depressed mood

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026